Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries

Published by: GBI Research

Published: Sep. 1, 2011 - 171 Pages

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Respiratory Disorders Therapeutics Market to 2017 - Introduction

2.1 GBI Research Report Guidance

3 Respiratory Disorders Therapeutics Market to 2017 - Market Overview

3.1 Introduction

3.2 Revenue Forecasts for Respiratory Disorders Therapeutics Market

3.2.1 Revenues

3.2.2 Annual Cost of Therapy

3.3 Treatment Usage Patterns

3.4 Drivers and Barriers for Respiratory Disorders Therapeutics Market

3.4.1 Drivers for Respiratory Disorders

3.4.2 Barriers for Respiratory Disorders

4 Respiratory Disorders Therapeutics Market to 2017 - Geographical Landscape

4.1 The US

4.1.1 Revenue

4.1.2 Annual Cost of Therapy

4.1.3 Treatment Usage Pattern

4.2 Top Five Countries of Europe

4.2.1 Revenue

4.2.2 Annual Cost of Therapy

4.2.3 Treatment Usage Pattern

4.3 Japan

4.3.1 Revenue

4.3.2 Annual Cost of Therapy

4.3.3 Treatment Usage Pattern

5 Respiratory Disorders Therapeutics Market to 2017 - Therapeutic Landscape

5.1 Asthma

5.1.1 Introduction

5.1.2 Revenue

5.1.3 Annual Cost of Therapy

5.1.4 Treatment Usage Patterns

5.1.5 Treatment Flow Algorithm

5.1.6 Drivers and Barriers for Asthma

5.2 COPD

5.2.1 Introduction

5.2.2 Revenue

5.2.3 Annual Cost of Therapy

5.2.4 Treatment Usage Patterns

5.2.5 Treatment Flow Algorithm

5.2.6 Drivers and Barriers for COPD

5.3 Pulmonary Arterial Hypertension

5.3.1 Introduction

5.3.2 Revenue

5.3.3 Annual Cost of Therapy

5.3.4 Treatment Usage Patterns

5.3.5 Treatment Flow Algorithm

5.3.6 Drivers and Barriers for Pulmonary Arterial Hypertension

5.4 Cystic Fibrosis

5.4.1 Introduction

5.4.2 Revenue

5.4.3 Annual Cost of Therapy

5.4.4 Treatment Usage Patterns

5.4.5 Treatment Flow Algorithm

5.4.6 Drivers and Barriers for Cystic Fibrosis

5.5 Allergic Rhinitis

5.5.1 Introduction

5.5.2 Revenue

5.5.3 Annual Cost of Therapy

5.5.4 Treatment Usage Patterns

5.5.5 Treatment Flow Algorithm

5.5.6 Drivers and Barriers for Allergic Rhinitis

5.6 Idiopathic Pulmonary Fibrosis

5.6.1 Introduction

5.6.2 Revenue

5.6.3 Annual Cost of Therapy

5.6.4 Treatment Usage Patterns

5.6.5 Treatment Flow Algorithm

5.6.6 Drivers and Barriers for Idiopathic Pulmonary Fibrosis

5.7 Bronchitis

5.7.1 Introduction

5.7.2 Revenue

5.7.3 Annual Cost of Therapy

5.7.4 Treatment Usage Patterns

5.7.5 Treatment Flow Algorithm

5.7.6 Drivers and Barriers for Bronchitis

6 Respiratory Disorders Therapeutics Market to 2017 - Product Pipeline Analysis

6.1 Introduction

6.1.1 Research and Development Pipeline - Asthma

6.1.2 Research and Development Pipeline - COPD

6.1.3 Research and Development Pipeline - Pulmonary Arterial Hypertension

6.1.4 Research and Development Pipeline - Cystic Fibrosis

6.1.5 Research and Development Pipeline - Allergic Rhinitis

6.1.6 Research and Development Pipeline - Idiopathic Pulmonary Fibrosis

6.1.7 Research and Development Pipeline - Bronchitis

6.2 Profiles of Promising Drugs in the Respiratory Disorders Therapeutics Market

6.2.1 Bilastine

6.2.2 Sublivac (Extracts of Allergens)

6.2.3 Duonase (Azelastine + Fluticasone)

6.2.4 Riociguat

6.2.5 VX-770

6.2.6 Indacaterol

6.2.7 NVA237 (Glycopyrronium Bromide)

6.2.8 Aclidinium Bromide

7 Respiratory Disorders Therapeutics Market to 2017 - Competitive Landscape

7.1 Market Share Analysis: Respiratory Disorders Market

7.2 Drug Profile of Major Marketed Products

7.2.1 Advair Diskus (fluticasone propionate and salmeterol inhalation powder)

7.2.2 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol)

7.2.3 Singulair (montekeulast sodium)

7.2.4 Tracleer

7.2.5 Nasonex (mometasone furoate monohydrate)

7.3 Competitive Profiling

7.3.1 AstraZeneca

7.3.2 GlaxoSmithKline

7.3.3 Merck & Co., Inc.

7.3.4 Actelion

7.3.5 Novartis

8 Respiratory Disorders Therapeutics Market to 2017 - M&A Landscape

8.1 M&A Landscape

8.1.1 M&A Deals by Year

8.1.2 M&A Deals by Value

8.1.3 M&A Deals by Value ($)

8.1.4 M&A Deals by Geography

8.1.5 M&A Deals by Deal Type

8.1.6 M&A Deals by Deal Sub-Type

8.2 R&D Licensing Agreements

8.2.1 Deals by Year

8.2.2 Deals by Geography

8.2.3 Deals by Value ($)

8.2.4 Licensing Agreements by Value ($)

8.3 Co-Development Agreements

8.3.1 Deals by Year

8.3.2 Deals by Geography

9 Respiratory Disorders Therapeutics Market to 2017 - Appendix

9.1 Market Definitions

9.2 Abbreviations

9.3 Research Methodology

9.3.1 Coverage

9.3.2 Secondary Research

9.3.3 Primary Research

9.3.4 Section Wise Methodology

9.3.5 Expert Panel Validation

9.4 Contact Us

9.5 Disclaimer

9.6 Sources

1.1 List of Tables

Table 1: Respiratory Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010

Table 2: Respiratory Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017

Table 3: Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn), 2002-2010

Table 4: Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn), 2010-2017

Table 5: Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010

Table 6: Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017

Table 7: Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010

Table 8: Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017

Table 9: Respiratory Disorders Therapeutics Market, The US, Revenue, ($bn), 2002-2010

Table 10: Respiratory Disorders Therapeutics Market, The US, Revenue Forecasts, ($bn), 2010-2017

Table 11: Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2002-2010

Table 12: Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2010-2017

Table 13: Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002-2010

Table 14: Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns, (million), 2010-2017

Table 15: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue, ($bn), 2002-2010

Table 16: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue, ($bn), 2010-2017

Table 17: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Share by Country, ($bn), 2002-2010

Table 18: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($bn), 2010-2017

Table 19: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2010

Table 20: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2010-2017

Table 21: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002-2010

Table 22: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2010-2017

Table 23: Respiratory Disorders Therapeutics Market, Japan, Revenue, ($bn), 2002-2010

Table 24: Respiratory Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2010-2017

Table 25: Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002-2010

Table 26: Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2010-2017

Table 27: Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002-2010

Table 28: Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2010-2017

Table 29: Asthma Therapeutics Market, Global, Revenue, ($bn), 2002-2010

Table 30: Asthma Therapeutics Market, Global, Revenue Forecasts, ($bn), 2010-2017

Table 31: Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2002-2010

Table 32: Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2010-2017

Table 33: Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010

Table 34: Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017

Table 35: Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010

Table 36: Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017

Table 37: COPD Therapeutics Market, Global, Revenue, ($m), 2002-2010

Table 38: COPD Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017

Table 39: COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010

Table 40: COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017

Table 41: COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010

Table 42: COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017

Table 43: COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010

Table 44: COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017

Table 45: Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue, ($m), 2002-2010

Table 46: Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017

Table 47: Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010

Table 48: Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017

Table 49: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010

Table 50: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017

Table 51: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2010

Table 52: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010-2017

Table 53: Cystic Fibrosis Therapeutics Market, Global, Revenue, ($m), 2002-2010

Table 54: Cystic Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017

Table 55: Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010

Table 56: Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017

Table 57: Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010

Table 58: Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017

Table 59: Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2010

Table 60: Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010-2017

Table 61: Allergic Rhinitis Therapeutics Market, Global, Revenue, ($m), 2002-2010

Table 62: Allergic Rhinitis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017

Table 63: Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010

Table 64: Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017

Table 65: Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010

Table 66: Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017

Table 67: Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010

Table 68: Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017

Table 69: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue, ($m) 2002-2010

Table 70: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m) 2010-2017

Table 71: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m) 2002-2010

Table 72: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m) 2010-2017

Table 73: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010

Table 74: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($) 2010-2017

Table 75: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2010

Table 76: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010-2017

Table 77: Bronchitis Therapeutics Market, Global, Revenue ($m), 2002-2010

Table 78: Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017

Table 79: Bronchitis Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2010

Table 80: Bronchitis Therapeutics Market, Global, Geographical Segmentation ($m), 2010-2017

Table 81: Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010

Table 82: Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017

Table 83: Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010

Table 84: Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017

Table 85: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Phase, 2011

Table 86: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Indication, 2011

Table 87: Asthma Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011

Table 88: Asthma Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011

Table 89: Asthma Therapeutics Market, Pipeline, Phase I Molecules, 2011

Table 90: Asthma Therapeutics Market, Pipeline, Phase II Molecules, 2011

Table 91: Asthma Therapeutics Market, Pipeline, Phase III Molecules, 2011

Table 92: Asthma Therapeutics Market, Pipeline, NDA Filed Molecules, 2011

Table 93: COPD Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011

Table 94: COPD Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011

Table 95: COPD Therapeutics Market, Pipeline, Phase I Molecules, 2011

Table 96: COPD Therapeutics Market, Pipeline, Phase II Molecules, 2011

Table 97: COPD Therapeutics Market, Pipeline, Phase III Molecules, 2011

Table 98: COPD Therapeutics Market, Pipeline, NDA Filed Molecules, 2011

Table 99: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011

Table 100: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Phase I Molecules, 2011

Table 101: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Phase II Molecules, 2011

Table 102: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, Phase III Molecules, 2011

Table 103: Pulmonary Arterial Hypertension Therapeutics Market, Pipeline, NDA Molecules, 2011

Table 104: Cystic Fibrosis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011

Table 105: Cystic Fibrosis Therapeutics Market, Pipeline, Phase I Molecules, 2011

Table 106: Cystic Fibrosis Therapeutics Market, Pipeline, Phase II Molecules, 2011

Table 107: Cystic Fibrosis Therapeutics Market, Pipeline, Phase III Molecules, 2011

Table 108: Cystic Fibrosis Therapeutics Market, Pipeline, NDA Filed Molecules, 2011

Table 109: Allergic Rhinitis Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011

Table 110: Allergic Rhinitis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011

Table 111: Allergic Rhinitis Therapeutics Market, Pipeline, Phase I Molecules, 2011

Table 112: Allergic Rhinitis Therapeutics Market, Pipeline, Phase II Molecules, 2011

Table 113: Allergic Rhinitis Therapeutics Market, Pipeline, Phase III Molecules, 2011

Table 114: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011

Table 115: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, IND Filed Molecules, 2011

Table 116: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Phase I Molecules, 2011

Table 117: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Phase II Molecules, 2011

Table 118: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, Phase III Molecules, 2011

Table 119: Idiopathic Pulmonary Fibrosis Therapeutics Market, Pipeline, NDA Filed Molecules, 2011

Table 120: Bronchitis Therapeutics Market, Pipeline, Discovery Stage Molecules, 2011

Table 121: Bronchitis Therapeutics Market, Pipeline, Pre-Clinical Stage Molecules, 2011

Table 122: Bronchitis Therapeutics Market, Pipeline, Phase I Molecules, 2011

Table 123: Bronchitis Therapeutics Market, Pipeline, Phase II Molecules, 2011

Table 124: Bronchitis Therapeutics Market, Pipeline, Phase III Molecules, 2011

Table 125: Bronchitis Therapeutics Market, Pipeline, NDA Filed Molecules, 2011

Table 126: Respiratory Disorders Therapeutics Market to 2017, Sales of Major Marketed Products, ($m), 2010

Table 127: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2011

Table 128: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Geography, 2004-2011

Table 129: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Deal Type, 2004-2011

Table 130: Respiratory Disorders Therapeutics Market, Global, Deals by Deal Sub-Type, 2004-2011

Table 131: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2011

Table 132: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Value ($m), 2004-2011

Table 133: Respiratory Disorders Therapeutics Market, Global, Co-Development Agreements by Geography, 2004-2011

1.2 List of Figures

Figure 1: Respiratory Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017

Figure 2: Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn), 2002-2017

Figure 3: Respiratory Disorders Therapeutics Market, Global, Branded and Generic Share (%), 2010

Figure 4: Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017

Figure 5: Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017

Figure 6: Respiratory Disorders Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 7: Respiratory Disorders Therapeutics Market, The US, Revenue Forecasts, ($bn), 2002-2017

Figure 8: Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2002-2017

Figure 9: Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002-2017

Figure 10: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue Forecasts, ($bn), 2002-2017

Figure 11: Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue Share by Country Forecasts, ($bn), 2002-2017

Figure 12: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2017

Figure 13: Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002-2017

Figure 14: Respiratory Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2002-2017

Figure 15: Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002-2017

Figure 16: Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002-2017

Figure 17: Asthma Therapeutics Market, Global, Revenue Forecasts, ($bn), 2002-2017

Figure 18: Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2002-2017

Figure 19: Asthma Therapeutics Market, Global, Branded and Generic Share, (%), 2010

Figure 20: Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017

Figure 21: Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2017

Figure 22: Asthma Therapeutics Market, Global, Treatment Flow Algorithm, 2010

Figure 23: Asthma Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 24: COPD Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017

Figure 25: COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017

Figure 26: COPD Therapeutics Market, Global, Branded and Generic Share, (%), 2010

Figure 27: COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017

Figure 28: COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2017

Figure 29: COPD Therapeutics Market, Global, Treatment Flow Algorithm - 1, 2010

Figure 30: COPD Therapeutics Market, Global, Treatment Flow Algorithm - 2, 2010

Figure 31: COPD Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 32: Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017

Figure 33: Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017

Figure 34: Pulmonary Arterial Hypertension Therapeutics Market, Global, Branded and Generic Share, (%), 2010

Figure 35: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017

Figure 36: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017

Figure 37: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Flow Algorithm, 2010

Figure 38: Pulmonary Arterial Hypertension Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 39: Cystic Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017

Figure 40: Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017

Figure 41: Cystic Fibrosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010

Figure 42: Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017

Figure 43: Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017

Figure 44: Cystic Fibrosis Therapeutics Market, Global, Treatment Flow Algorithm, 2010

Figure 45: Cystic Fibrosis Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 46: Allergic Rhinitis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017

Figure 47: Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2017

Figure 48: Allergic Rhinitis Therapeutics Market, Global, Branded and Generic Share, (%), 2010

Figure 49: Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017

Figure 50: Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017

Figure 51: Allergic Rhinitis Therapeutics Market, Global, Treatment Flow Algorithm, 2010

Figure 52: Allergic Rhinitis Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 53: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m) 2002-2017

Figure 54: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m) 2002-2017

Figure 55: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010

Figure 56: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017

Figure 57: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017

Figure 58: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Flow Algorithm, 2010

Figure 59: Allergic Rhinitis Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 60: Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017

Figure 61: Bronchitis Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017

Figure 62: Bronchitis Therapeutics Market, Global, Branded and Generic Share (%), 2010

Figure 63: Bronchitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017

Figure 64: Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017

Figure 65: Bronchitis Therapeutics Market, Global, Treatment Flow Algorithm, 2010

Figure 66: Bronchitis Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 67: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Phase (%), 2011

Figure 68: Respiratory Disorders Therapeutics Market, Global Product Pipeline by Indication (%), 2011

Figure 69: Respiratory Disorders Therapeutics Market, Global, Market Share Analysis by Company (%), 2010

Figure 70: Respiratory Disorders Therapeutics Market, AstraZeneca, Company Overview, 2011

Figure 71: Respiratory Disorders Therapeutics Market, AstraZeneca, SWOT Analysis, 2011

Figure 72: Respiratory Disorders Therapeutics Market, GSK, Company Overview, 2011

Figure 73: Respiratory Disorders Therapeutics Market, GSK, SWOT Analysis, 2011

Figure 74: Respiratory Disorders Therapeutics Market, Merck, Company Overview, 2011

Figure 75: Respiratory Disorders Therapeutics Market, Merck, SWOT Analysis, 2011

Figure 76: Respiratory Disorders Therapeutics Market, Actelion, Company Overview, 2011

Figure 77: Respiratory Disorders Therapeutics Market, Actelion, SWOT Analysis, 2011

Figure 78: Respiratory Disorders Therapeutics Market, Novartis, Company Overview, 2011

Figure 79: Respiratory Disorders Therapeutics Market, Novartis, SWOT Analysis, 2011

Figure 80: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Year, 2004-2011

Figure 81: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Value (%), 2004-2011

Figure 82: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2011

Figure 83: Respiratory Disorders Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2011

Figure 84: Respiratory Disorders Therapeutics Market, Global, Deals by Deal Sub-Type (%), 2004-2011

Figure 85: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Year, 2004-2011

Figure 86: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2011

Figure 87: Respiratory Disorders Therapeutics Market, Global, Licensing Agreements by Value (%), 2004-2011

Figure 88: Respiratory Disorders Therapeutics Market, Global, Co-Development Agreements by Year, 2004-2011

Figure 89: Respiratory Disorders Therapeutics Market, Global, Co-Development Agreements by Geography (%), 2004-2011

Figure 90: GBI Research Market Forecasting Model

Abstract

• The report analyzes market characterization, pipeline analysis and key M&A trends in the asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis therapeutics market.
• Data and analysis on the global respiratory disorders market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
• Annualized market data for the respiratory disorders market from 2002-2010 with forecasts to 2017.
• Market data on the therapeutic landscape which covers asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis, including market size, market share and annual cost of therapy, treatment flow algorithm and branded and generic share.
• Key drivers and restraints that have had a significant impact on the market and on each indication.
• The competitive landscape of the global respiratory disorders therapeutics market which includes companies such as AstraZeneca, GlaxoSmithKline, Merck, Actelion, and Novartis.
• Key M&A activities and licensing agreements that took place from 2005-2011 in the global respiratory disorders market.

• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
• Device a more tailored country strategy through the understanding of key drivers and barriers of the respiratory disorders market.
• Develop key strategic initiatives by understanding the key focus areas and top selling antibacterial molecules of leading companies.
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.